Healthcare Consulting India

16/03/2022

The new study, which appears in the journal Neurology, started with a basic question about beta-amyloid production, its clearance in people, and why amyloid plaques develop as individuals get older and develop AD. “We launched our study to measure that amyloid-beta 42 is specifically impaired in its clearance out of the brain and central nervous system,” senior study author Dr. Bateman explained to Medical News Today. They then looked at the formation of beta-amyloid 42 and how it traveled from the brain into the blood.

New research suggests that a novel blood test could be a less invasive, inexpensive way of detecting Alzheimer's disease.

14/03/2022

A single combined-drug inhaler used as needed protects adults with mild asthma from worsening illness and hospital stays, a recent commentary on Cochrane systematic review data reports.But long-term medication and use by children under 12 years of age need to be studied, and regulatory agencies in countries including the United States have not yet approved the combined delivery.

The inhaler helps adults with mild asthma avoid flareups and hospital stays, but more study in children, and FDA approval, are needed, according to a Cochrane systematic review.

01/03/2022

Vascular dementia is the second leading cause of dementia following Alzheimer’s. It occurs due to the interruption of blood and oxygen supply to the brain, which damages the blood vessels. Low oxygen levels elsewhere in the body can also disrupt other critical organs and their functions. For instance, reduced blood supply to the heart can lead to cardiovascular disease and heart attacks. Because low oxygen levels in the body can cause life threatening conditions, it seems paradoxical to deprive a tissue or organ of oxygen to confer benefits. However, a group of researchers is examining some potential benefits of exposure to low oxygen levels, also known as hypoxia.

A study in mice found that hypoxia increased animals' resistance to the cognitive deficits of dementia. They also passed this resistance to their offspring.

17/02/2022

More than 1 billion people worldwide experience migraine headaches. Globally, migraine is the second most disabling medical condition, after lower back pain, in terms of years lived with disability.

The condition is about three times as common in women as it is in men.

“Migraine is the most prevalent and one of the most disabling neurological diseases in the world,” Dr. Roger Cady, a board member of the National Headache Foundation in Chicago, told Medical News Today. Dr. Cady was not involved with the study

According to the largest ever genome study of migraine, this prevalent and disabling neurological disease may be linked to genetic risk factors.

28/12/2021

“The data from this phase 3 study support our view that P2B001 can provide clinical benefits comparable to higher doses of commercially available dopamine agonists, while mitigating the side effects typically associated with this class of medicine such as somnolence, orthostatic hypotension and hallucinations,” said Dr Sheila Oren, MD, MBA, Chief Executive Officer of Pharma Two B.
The Company plans to submit a New Drug Application for P2B001 to the Food and Drug Administration (FDA) in 2022.

The fixed-dose combination therapy was found to be superior to each component.

26/12/2021

Scientists have found that the active component of honeybee venom rapidly kills two types of difficult-to-treat breast cancer cells.

23/12/2021

Paxlovid is taken as three tablets taken together orally twice a day for 5 days, for a total of 30 tablets. Possible side effects include reduced sense of taste (ageusia), diarrhea, high blood pressure, and muscle aches.The authorization arrives as the US faces a surge in Omicron case numbers. Evidence points to waning effectiveness of some monoclonal antibody treatments as Americans struggle to maintain some sense of tradition and normalcy around the holidays.

Although the agency was expected to also authorize an antiviral from Merck, only Pfizer's was cleared for use Wednesday.

15/12/2021

Gideon Meyerowitz-Katz is an epidemiologist and writer based in Sydney, Australia. His work covers chronic disease, the pandemic response, and more recently, error detection in science. In this op-ed, he discusses issues with research that have become increasingly apparent during the pandemic.

In this op-ed, epidemiologist Gideon Meyerowitz-Katz discusses problems with medical research that have become increasingly apparent during the pandemic.

14/12/2021

A recent study concluded that assessing the ratio of lipid transporters in the blood can predict cardiovascular events 20 years before they occur.

30/11/2021

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients. https://endpts.com/sp/at-the-inflection-point-for-the-next-generation-of-cancer-immunotherapy/

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and reg...

29/11/2021

“The sequence of this variant, currently called B.1.1.529, was first uploaded by Hong Kong from a case of someone traveling from South Africa,” the British health minister, Sajid Javid, said. “The UK was the first country to identify the potential threat of this new variant and to alert international partners. Further cases have been identified in South Africa and in Botswana, and it is highly likely that it has now spread to other countries.” https://endpts.com/new-coronavirus-mutation-takes-flight-around-the-globe-as-health-officials-scramble-to-mount-new-defenses/

As Americans were waking up for their Black Friday rituals, they were greeted with the news that a new mutation of the Covid-19 virus has appeared and been sequenced — after it caught an international flight to Hong Kong. And two of the leading Covid-19 vaccine developers promised delivery of

25/11/2021

Takeda announced that the U.S. FDA has approved Livtencity (maribavir) for the treatment of adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. https://trialsitenews.com/takeda-announces-u-s-fda-approval-of-livtencity-maribavir-for-post-transplant-cytomegalovirus-refractory-to-conventional-antiviral-therapies/

Takeda announced that the U.S. FDA has approved Livtencity (maribavir) for the treatment of adults and pediatric patients (12 years of age or older and